All In Biotech

Drug Trial Radar · NCT05930704

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection Administered Subcutaneously to Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: Jul 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

45

Planned (sponsor's estimate)

Start

Jul 4, 2023

Primary completion

Apr 12, 2025

Study completion Apr 12, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective was to evaluate the safety and tolerability of SHR-2017 after a single subcutaneous (SC) injection in postmenopausal women

Conditions

  • Osteoporosis

Interventions

  • SHR-2017 injectionDrug

    Randomized participants of multiple dose cohorts will receive a single subcutaneous dose of SHR-2017 injection.

  • PlaceboDrug

    Randomized participants will receive a single SC injection dose of matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: From day 1 up to 9 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Shandong First Medical University

    Jinan, Shangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.